Checkpoint Capital L.P. Rhythm Pharmaceuticals, Inc. Transaction History
Checkpoint Capital L.P.
- $215 Billion
- Q2 2025
A detailed history of Checkpoint Capital L.P. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 1,060,000 shares of RYTM stock, worth $105 Million. This represents 31.21% of its overall portfolio holdings.
Number of Shares
1,060,000
Previous 907,240
16.84%
Holding current value
$105 Million
Previous $48.1 Billion
39.38%
% of portfolio
31.21%
Previous 26.37%
Shares
7 transactions
Others Institutions Holding RYTM
# of Institutions
246Shares Held
64MCall Options Held
210KPut Options Held
575K-
Black Rock Inc. New York, NY6.74MShares$668 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$555 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.56MShares$551 Million7.68% of portfolio
-
Primecap Management CO Pasadena, CA4.88MShares$483 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$355 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $5.52B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...